Levosimendan Pharmacokinetics in Children (LevoCorKids)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01704131|
Recruitment Status : Recruiting
First Posted : October 11, 2012
Last Update Posted : August 20, 2019
|Condition or disease|
|Acute Heart Failure|
Rationale: Levosimendan, a calcium-sensitizer, is a relatively new inotropic drug with the benefit over conventional inotropes that it does not increase myocardial oxygen demand or lead to arrhythmias. Levosimendan has a relatively unique pharmacokinetic profile, after a 24 hour infusion its clinical effects remain for several days. This is achieved through the continuing haemodynamic effects of its active metabolites, which have a half life of approximately 80 hours compared to 1 hour of Levosimendan itself. Levosimendan has been extensively studied in adults and is used in ischemic heart disease, acute heart failure, chronic heart failure, following cardiac surgery, and in septic shock. Due to the inotropic properties and its strong pulmonary vasodilatory effect, Levosimendan could also be very useful as perioperative therapy in children with congenital heart disease, low cardiac output, or pulmonary artery hypertension.
Although experience with levosimendan in children is still scarce in the literature, initial reports have been promising and Levosimendan is used more and more often as a (rescue) therapy in children with heart failure. However, current dosing regimens in children are based on adult pharmacokinetic evidence. One pediatric report suggests that the pharmacokinetic profile of a single loading dose of Levosimendan is probably similar in children older than 6 months compared to adults. The pharmacokinetic profile of a 24-hour infusion of Levosimendan has not yet been studied in children. It is very important to study the pharmacokinetics of this useful drug in different age groups because of the diversity of the population due to age, volume of distribution, ontogeny of the metabolizing enzymes, and the influence of disease state on pharmacokinetics and pharmacodynamics.
Objective: To describe the pharmacokinetic profile of a 24 hour infusion of levosimendan and its active metabolites in children with acute or chronic heart failure.
Study design: Observational study of Levosimendan levels in children treated with Levosimendan because of heart failure.
Study population: Children (< 16 years) admitted to the pediatric intensive care unit, with acute or chronic heart failure.
Intervention (if applicable): no intervention Main study parameters/endpoints: The primary endpoint of the study is to describe the pharmacokinetic profile by determining plasma levels of levosimendan and its metabolites during 12 days following a 24-hour infusion in children with heart failure in different age groups. Secondary endpoints are the clinically measured hemodynamic variables (heart rate, bloodpressure, lactate, troponin, pro-BNP, venous saturation) and echocardiographic variables (ejection fraction, shortening fraction, tissue Doppler) of all patients.
|Study Type :||Observational|
|Estimated Enrollment :||36 participants|
|Official Title:||Pharmacokinetics of Levosimendan in Children With Acute Heart Failure|
|Actual Study Start Date :||November 2012|
|Estimated Primary Completion Date :||September 1, 2019|
|Estimated Study Completion Date :||September 1, 2019|
children > 6 months
children > 6 months of age
children < 6 months
children < 6 months
- the pharmacokinetic profile of levosimendan and is metabolites [ Time Frame: 3 years ]AUC, Cmax, half-life, steady state concentration, plasma clearance, volume of distribution
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01704131
|Contact: Peter P Roeleveld, MD||+31715261677 ext firstname.lastname@example.org|
|Contact: H E Bunker-Wiersma, MD, Phd||+31715261677 ext 8775||H.E.Bunker-Wiersma@lumc.nl|
|PICU Leiden University Medical Center||Recruiting|
|Principal Investigator: Peter P Roeleveld, MD|
|Principal Investigator:||Peter P Roeleveld, MD||Leiden University Medical Center|
|Study Chair:||Heleen E Bunker-Wiersma, MD, phd||Leiden University Medical Center|